论文部分内容阅读
转移性黑素瘤病人平均生存期仅4～6月。1989年报道的美国Mayo Clinic 502例采用化疗的晚期黑素瘤,五年生存率仅2%。作者曾注射BCG于黑素瘤皮肤转移灶内借以提高病人的主动免疫力,从而使包括未接受注射的转移灶得以消退。受此启发,他们将随机选用混有BCG并经辐射处理的同种异体黑色素瘤细胞制备的肿瘤疫苗(TCV)作皮内及淋巴内注射,获得同样的主动免疫。但对TCV高度敏感者仅35%,其后发现TCY所含黑素瘤相关抗原(MAA)数值不高。1984年作者进而用富含6种MAA的3
The average survival of patients with metastatic melanoma is only 4 to 6 months. In 1989, 502 cases of advanced melanoma were treated with chemotherapy at the Mayo Clinic in the United States. The five-year survival rate was only 2%. The authors have injected BCG into melanoma skin metastasis to enhance the patient’s active immunity so that metastases including uninjected injections can be regressed. Inspired by this, they will randomly select tumor vaccines (TCV) prepared from allogeneic melanoma cells mixed with BCG and irradiated with intradermal and intralymphatic injections to obtain the same active immunity. However, only 35% of individuals with high TCV sensitivity were found to have low levels of melanoma-associated antigen (MAA). In 1984, the author further used 3 kinds of MAA rich in 3